Menu
Recruiting NCT05448365

Vitamin D, Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in Uterine Fibroid

No phase Interventional Uterine Fibroids D-chiro-inositol Inositol Epigallocatechin Gallate

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol, Placebo.
Who it may be relevant to
Registry conditions: Uterine Fibroids, D-chiro-inositol, Inositol, Epigallocatechin Gallate. Basic parameters: 30 years — 40 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The Use of Vitamin D in Combination With Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in the Treatment of Women With Uterine Fibroid

Overview

The study will evaluate the impact on uterine fibroids' volume of a combination of natural molecules including Epigallocatechin gallate, Vitamin D, D-chiro-inositol and Vitamin B6. The patients will be evaluated at baseline and after three months of treatment with placebo or product.

Interventions

  • Dietary supplement Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol
    The patients will take for three months two tablets per day each containing 150mg epigallocatechin gallate, 25 mg D-chiro-inositol, 5mg Vitamin B6 and 25μg Vitamin D
  • Dietary supplement Placebo
    Maltodextrines

Primary outcome measures

  • Diameter [Time frame: 3 months]
Secondary outcome measures (4)
  • Volume [Time frame: 3 months]
  • Need for surgery [Time frame: 3 months]
  • pVEGF-R [Time frame: 3 months]
  • Marker of cellular proliferation [Time frame: 3 months]

Eligibility criteria

Inclusion criteria

  • uterine fibroid with diameter greater than or equal to 4cm or multiple fibroids
  • eligible for surgery
  • symptoms like menometrorrhagia or pelvic pain

Exclusion criteria

  • BMI>30
  • currently pregnant or breastfeeding
  • diabetic
  • suspect of malignancy
  • diagnosis of cancer

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

Italy · 2 centers
  • Ospedale Dario camberlingo — Francavilla Fontana
  • Ospedale Veris Delli Ponti — Scorrano

Identifiers

NCT: NCT05448365 · DELPHYS PLUS

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗